SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances
10 references·16 citing·48 second hop
Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances (2005)Productivity in pharmaceutical–biotechnol…Biotech‐Pharmaceutical Alliances as a Signal of Asset and Firm Quality (2005)Biotech‐Pharmaceutical Allian…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Risks in new drug development: Approval success rates for investigational drugs (2001)Risks in new drug development…Network Position and Firm Performance: Organizational Returns to Collaboration in the Biotechnology Industry (2000)Network Position and Firm Per…The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry (1998)The Control of Technology All…Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)Scale, Scope, and Spillovers:…Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)Interorganizational Collabora…Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…Joint ventures: Theoretical and empirical perspectives (1988)Joint ventures: Theoretical a…Corporate financing and investment decisions when firms have information that investors do not have (1984)Corporate financing and inves…Amazon: A story of accumulation through intellectual rentiership and predation (2020)Amazon: A story of accumulati…Economics of the Pharmaceutical Industry (2018)Economics of the Pharmaceutic…Mechanisms of Hybrid Governance: Administrative Committees in Non-Equity Alliances (2015)Mechanisms of Hybrid Governan…Risk in Vaccine Research and Development Quantified (2013)Risk in Vaccine Research and …Technological development at the boundaries of the firm: a knowledge‐based examination in drug development (2012)Technological development at …How does openness affect the importance of incentives for innovation? (2012)How does openness affect the …Benefiting From Alliance Portfolio Diversity (2012)Benefiting From Alliance Port…Scale effects of R&D as reflected in earnings and returns (2011)Scale effects of R&D as refle…Policies and Incentives for Promoting Innovation in Antibiotic Research (2010)Policies and Incentives for P…Contractibility and the Design of Research Agreements (2010)Contractibility and the Desig…Spending on new drug development1 (2009)Spending on new drug developm…A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development (2009)A Breath of Fresh Air? Firm T…Mergers and innovation in big pharma (2008)Mergers and innovation in big…From Invention to Innovation: Conversion Ability in Product Development (2006)From Invention to Innovation:…Experience and scale and scope economies: trade‐offs and performance in development (2006)Experience and scale and scop…Diagnostics and biomarker development: priming the pipeline (2006)Diagnostics and biomarker dev…The Strength of Weak Ties (1973)Economic Action and Social Structure: The Problem of Embeddedness (1985)Absorptive Capacity: A New Perspective on Learning and Innovation (1990)Core and periphery in networks (2007)Learning at the boundaries in an “Open Regional Innovation System”: A focus on firms’ innovation strategies in the Emilia Romagna life science industry (2010)Contemporary Social Psychological Theories (2020)An Evolutionary Theory of Economic Change. (1983)Innovation and Learning: The Two Faces of R & D (1989)The Relational View: Cooperative Strategy and Sources of Interorganizational Competitive Advantage (1998)Dynamic capabilities: what are they? (2000)The Theory of Economic Development (2003)Open for innovation: the role of openness in explaining innovation performance among U.K. manufacturing firms (2005)The Iron Cage Revisited: Institutional Isomorphism and Collective Rationality in Organizational Fields (1983)The Economic Institutions of Capitalism (1987)Where Do Interorganizational Networks Come From? (1999)A Resource-Based Theory of Strategic Alliances (2000)Strategic networks (2000)The iron cage revisited institutional isomorphism and collective rationality in organizational fields (2004)Economic Welfare and the Allocation of Resources for Invention (1962)The Costs and Benefits of Ownership: A Theory of Vertical and Lateral Integration (1986)Firms, Contracts, and Financial Structure (1995)Networks and Economic life (2003)Four formal(izable) theories of the firm? (2005)Closed or open innovation? Problem solving and the governance choice (2013)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)The Market for "Lemons": Quality Uncertainty and the Market Mechanism (1970)Theory of the firm: Managerial behavior, agency costs and ownership structure (1976)Determinants of corporate borrowing (1977)The Capital Structure Puzzle (1984)A Survey of Corporate Governance (1997)Information asymmetry, corporate disclosure, and the capital markets: A review of the empirical disclosure literature (2001)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)How Drugs are Developed and Approved by the FDA: Current Process and Future Directions (2014)Market size and pharmaceutical innovation (2015)Costs of Drug Development and Research and Development Intensity in the US, 2000-2018 (2024)Economics of New Oncology Drug Development (2007)Deconstructing the Drug Development Process: The New Face of Innovation (2010)Changing R&D models in research-based pharmaceutical companies (2016)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)The Burden of Knowledge and the “Death of the Renaissance Man”: Is Innovation Getting Harder? (2008)Fifty Years of Empirical Studies of Innovative Activity and Performance (2010)
this work references cited by second hop

References

  • 1984Corporate financing and investment decisions when firms have information that investors do not have18,936 cited
  • 1996Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology8,498 cited
  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 1988Joint ventures: Theoretical and empirical perspectives3,335 cited
  • 1996Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery1,389 cited
  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 1998The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry634 cited
  • 2001Risks in new drug development: Approval success rates for investigational drugs450 cited
  • 2000Network Position and Firm Performance: Organizational Returns to Collaboration in the Biotechnology Industry284 cited
  • 2005Biotech‐Pharmaceutical Alliances as a Signal of Asset and Firm Quality173 cited

Cited by

  • 2009Spending on new drug development1277 cited
  • 2013Risk in Vaccine Research and Development Quantified253 cited
  • 2006From Invention to Innovation: Conversion Ability in Product Development190 cited
  • 2018Economics of the Pharmaceutical Industry173 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2010Contractibility and the Design of Research Agreements172 cited
  • 2012Benefiting From Alliance Portfolio Diversity171 cited
  • 2008Mergers and innovation in big pharma161 cited
  • 2011Scale effects of R&D as reflected in earnings and returns158 cited
  • 2009A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development137 cited
  • 2006Experience and scale and scope economies: trade‐offs and performance in development126 cited
  • 2012How does openness affect the importance of incentives for innovation?125 cited
  • 2006Diagnostics and biomarker development: priming the pipeline118 cited
  • 2020Amazon: A story of accumulation through intellectual rentiership and predation116 cited
  • 2015Mechanisms of Hybrid Governance: Administrative Committees in Non-Equity Alliances112 cited
  • 2012Technological development at the boundaries of the firm: a knowledge‐based examination in drug development108 cited
  • 2010Policies and Incentives for Promoting Innovation in Antibiotic Research102 cited